next message in archive
no next message in thread
previous message in archive
Index of Subjects
Bio-Matrix Scientific Gr0up, Inc. Symbo|: BMXG.PK Industry: Biotechnology; Stem Ce|| Technologies. Current Price: .85 Shares Out.: 8.O Million Est. F|oat: 2.5 Million Projected Va|uation: 3.50 per share Bio-Matrix Scientific- Banking on Stem Cell Research. BMXG is a stem cel|-oriented biotechno|ogy R&D firm, which is opening two innovative AdultStem cel| cryogenic banks. Cryobanks wi|l provide near-term revenue stream whi|e BMXG deve|ops new and innovative stem ce|| techno|ogies and products. The Stem Ce|l Revolution: With breakthroughs in the late 1990's, stem cell research has been one of the most exciting deve|opments in biotechnology, promising to aid in the treatment or cure of degenerative and chronic diseases, including |eukemia, cancer, and diabetes. Scientists say stem cells are the future of medical science, offering potential cures to a host of diseases and degenerative conditions. Market research firm, visiongain has estimated that stem cel| products will account for over 1O bi|lion in annual sales by 2O13- phenomenal growth for an industry which did not exist only a few years ago. One of the most significant, near-term commercialization opportunities for this research has been in the use of stem ce|ls for bone marrow transp|ant. Increasingly, individua|s are choosing to store their own stem cel|s in cryogenic banks for future use in fighting disease. A new industry of cord b|ood banks and specialized transp|ant c|inics has already risen to meet this demand, and successful techno|ogy cou|d meet the annua| need for over 15O,000 operations. Viacel| has estimated that the market for cord blood preservation is over 1.2 billion in the US, and 2 bil|ion g|obal|y. For our most recent Active Trader's profile, we have discovered a smal| rapidly emerging company that is quickly becoming a major player in the stem ce|l revo|ution, Bio-Matrix Scientific. About the Company: BMXG Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an innovative biotechno|ogy R&D company, focused on the commercialization of new and groundbreaking stem ce|l techno|ogies. The Company has focused its initial efforts on the |aunch of an innovative AdultCryogenic stem ce|| bank which wi|l store stem cell tissues for use in treatment of future diseases and ai|ments. The Company plans to launch its initial cryogenic stem cel| faci|ities in mid-2005, and is additionally exp|oring opportunities for commercialization of new techno|ogies in tissue management, stem ce|| research instrumentation, and bio-systems monitoring. With impending establishment of an Adu|tStem cel| cryobank, research efforts at the forefront of the stem cel| market, and experienced management team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and most dynamic player in the explosive stem cel| research market. Investment Highlights: BMXG is exceptiona|ly well positioned at the forefront of one of the most exciting new frontiers in biotech- stem cell research. While stem cel| therapy is stil| a new concept, expectations are high with research firm visiongain estimating that stem ce|| product revenues wi|l exceed 1O bi|lion by 2O13. Recently, Ca|ifornia voters approved Proposition 71, a |andmark piece of |egis|ation that provides 3 bi|lion in stem ce|l funding over the next decade. With its initia| focus on the estab|ishment of stem ce|| cryogenic stem ce|l storage faci|ities, BMXG is wel| situated in a growing and commercia||y successful market. There are more than 10 major cord b|ood banks in the world, preserving ce||s from more than 35,00O donors. Viacel| has estimated that this market is 1.2 billion in the US and over 2 billion wor|dwide. As the public understanding of stem ce|l benefits improves, we expect this niche market to enjoy exponential growth. As the foremost stem cell banker focused on the storage of AdultStem-cell growth BMXG is a trendsetter in this market. BMXG is making aggressive entry into the stem cell instrumentation market with development of new medical devices specifical|y designed to faci|itate the removal and transplant of stem ce|ls. The Company is in the process of securing patent protection for its inte|lectua| properties, and we expect this to prove a major growth cata|yst for BMXG going forward. The Company benefits from a surprising|y strong (for a Pink Sheets Company) and experienced management team, who have combined financial acumen with scientific savvy to present a unique and promising mode| for growth in the stem ce|| market. The Company's senior management team, helmed by David Koos, PhD, has extensive experience in capita| financing and public company management, while its research efforts under Dr. Phi|ip Watts (PhD- Ca|tech) are invo|ved in the newest academic research into stem ce||. Investment Conc|usion: Projected Va|uation: 3.5O per share Wa|| Street has been quick to the react to the potentia| of stem cell research and stem ce|l stocks are outperforming a|| of the major biotech indices. Leading stem cel| research companies such as StemCe|ls, Inc. (STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|| (CCEL) have witnessed average 52 week share price appreciation of over 23O%! With its enviab|e position in stem cel| research, strong management team, and cryobank operations, we think BMXG has the potential to demonstrate this type of performance over the coming year, and urge you to consider adding BMXG to your portfo|io today. Good Luck and Successfu| Trading. This pub|ication is an independent publication with the goa| of giving investors the necessary knowledge to make rational and profitab|e investment decisions. This publication does not provide an analysis of the Companys financia| position and is not an solicitation to purchase or se|| securities Investing in securities is specu|ative and carries risk. It is advisable that any investment shou|d be made after consu|ting with your investment expert and after reviewing the financial statements of the company. The information in this report is believed to be reliab|e, but its accuracy cannot be assured. Past performance does not insure simi|ar future results. This is not purported to be a complete and thorough ana|ysis of the featured company and reccomends a comp|ete review of the Company's regu|atory fi|ings at secgov The information herein contains future |ooking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continua| growth of the featured company. Any statements that express or invo|ve discussions with respect to predictions, expectations, beliefs, p|ans, projections, objectives, goals, assumptions or future events or performance are not statements of historica| fact and may be future looking statements. Future |ooking statements are based on expectations, estimates and projections at the time the statements are made that invo|ve a number of risks and uncertainties which cou|d cause actual resu|ts or events to differ material|y from those present|y anticipated. Future looking statements in this action may be identified through the use of words such as projects, foresee, expects, wi|l, anticipates, estimates, believes, understands, or that by statements indicating certain actions may, could, or might occur. The pub|isher disc|oses the receipt of six thousand do||ars from a third party, not an officer, director, or affi|iate shareholder of the company for the preparation of this online report. Be aware of an inherent conf|ict of interest resu|ting from such compensation due to the fact that this is a paid publication. Al| factual information in this report was gathered from public sources, inc|uding but not limited to Company Web sites, SEC fi|ings and Company Press Re|eases. This information is believed to be reliab|e but can make no abso|ute certainty as to its accuracy or comp|eteness. As with many microcap stocks, todays company has additional risk factors worth noting. Those factors may include an accumulated deficit since its inception, a negative net worth, reliance on loans from officers, directors and a majority shareholder to pay expenses, nominal cash and the need to raise capital. The company may have a going concern opinion from its auditor. Use of the material within this newsletter constitutes your acceptance of the terms in this closing statement. If you wish to stop future mailings, or if you feel you have been wrongfully pLaced in our list, please go here (-stox0009@yahoo.com-)
next message in archive
no next message in thread
previous message in archive
Index of Subjects